Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Kirtland Hills Capital Management LLC

Kirtland Hills Capital Management LLC cut its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 12.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,495 shares of the medical research company’s stock after selling 633 shares during the period. Kirtland Hills Capital Management LLC’s holdings in Edwards Lifesciences were worth $333,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Los Angeles Capital Management LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $220,000. Prasad Wealth Partners LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $277,000. BankPlus Trust Department purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $844,000. Impax Asset Management Group plc boosted its stake in shares of Edwards Lifesciences by 34.6% in the fourth quarter. Impax Asset Management Group plc now owns 17,448 shares of the medical research company’s stock valued at $1,292,000 after purchasing an additional 4,484 shares during the period. Finally, W.G. Shaheen & Associates DBA Whitney & Co boosted its stake in shares of Edwards Lifesciences by 45.9% in the fourth quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 161,221 shares of the medical research company’s stock valued at $11,935,000 after purchasing an additional 50,744 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,489 shares of company stock valued at $2,002,829 in the last ninety days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $71.46 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a market capitalization of $42.15 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 4.82 and a beta of 1.11. The firm’s fifty day simple moving average is $72.78 and its 200-day simple moving average is $70.18.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on EW. Citigroup raised their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Truist Financial reiterated a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Barclays lifted their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Finally, Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.